Metronidazole-triazole conjugates: Activity against Clostridium difficile and parasites

被引:43
|
作者
Jarrad, Angie M. [1 ]
Karoli, Tomislav [1 ]
Debnath, Anjan [2 ]
Tay, Chin Yen [4 ]
Huang, Johnny X. [1 ]
Kaeslin, Geraldine [1 ]
Elliott, Alysha G. [1 ]
Miyamoto, Yukiko [3 ]
Ramu, Soumya [1 ]
Kavanagh, Angela M. [1 ]
Zuegg, Johannes [1 ]
Eckmann, Lars [3 ]
Blaskovich, Mark A. T. [1 ]
Cooper, Matthew A. [1 ]
机构
[1] Univ Queensland, Inst Mol Biosci, Div Chem & Struct Biol, Brisbane, Qld 4072, Australia
[2] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA
[3] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA
[4] Univ Western Australia, Marshall Ctr Infect Dis Res & Training, Perth, WA 6099, Australia
基金
英国惠康基金; 澳大利亚国家健康与医学研究理事会;
关键词
Nitroimidazole; Click chemistry; Antibiotic; Anaerobe; IN-VITRO; DRUG; RESISTANCE;
D O I
10.1016/j.ejmech.2015.06.019
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Metronidazole has been used clinically for over 50 years as an antiparasitic and broad-spectrum antibacterial agent effective against anaerobic bacteria. However resistance to metronidazole in parasites and bacteria has been reported, and improved second-generation metronidazole analogues are needed. The copper catalysed Huigsen azide-alkyne 1,3-dipolar cycloaddition offers a way to efficiently assemble new libraries of metronidazole analogues. Several new metronidazole-triazole conjugates (Mtz-triazoles) have been identified with excellent broad spectrum antimicrobial and antiparasitic activity targeting Clostridium difficile, Entamoeba histolytica and Giardia lambda. Cross resistance to metronidazole was observed against stable metronidazole resistant C. difficile and G.. lamblia strains. However for the most potent Mtz-triazoles, the activity remained in a therapeutically relevant window. (C) 2015 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
引用
收藏
页码:96 / 102
页数:7
相关论文
共 50 条
  • [41] Vaccines against Clostridium difficile
    Leuzzi, Rosanna
    Adamo, Roberto
    Scarselli, Maria
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (06) : 1466 - 1477
  • [42] Vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea
    Bishara, Jihad
    Wattad, Morad
    Paul, Mical
    CLINICAL INFECTIOUS DISEASES, 2007, 45 (12) : 1646 - 1647
  • [43] ORAL METRONIDAZOLE IN CLOSTRIDIUM DIFFICILE POSITIVE ANTIBIOTIC ASSOCIATED DIARRHEA
    BOLTON, RP
    GUT, 1980, 21 (10) : A921 - A921
  • [45] FAILURE RATE OF METRONIDAZOLE IN CLOSTRIDIUM DIFFICILE INFECTION: A RETROSPECTIVE STUDY
    Oh, Erin
    Abraham, Teena
    Saad, Nasser
    Vastey, Fabienne
    Balmir, Eric
    CRITICAL CARE MEDICINE, 2009, 37 (12) : A147 - A147
  • [46] Fucidic acid use in metronidazole nonresponders with Clostridium difficile infection
    Bektas, Mehmet
    Toeruener, Murat
    Cetinkaya, Hulya
    Soykan, Irfan
    Oezden, Ali
    DIGESTION, 2007, 75 (04) : 177 - 178
  • [47] EFFICACY OF PARENTERAL METRONIDAZOLE FOR THE TREATMENT OF CLOSTRIDIUM-DIFFICILE COLITIS
    FRIEDENBERG, F
    ILAGAN, P
    LEVINE, G
    GASTROENTEROLOGY, 1995, 108 (04) : A819 - A819
  • [48] Can metronidazole still be used for treatment of Clostridium difficile infections?
    Huang H.
    Nord C.E.
    Current Infectious Disease Reports, 2009, 11 (1) : 3 - 6
  • [49] Analysis of metronidazole susceptibility in different Clostridium difficile PCR ribotypes
    Moura, Ines
    Spigaglia, Patrizia
    Barbanti, Fabrizio
    Mastrantonio, Paola
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2013, 68 (02) : 362 - 365
  • [50] Treatment of Metronidazole-Refractory Clostridium difficile Enteritis with Vancomycin
    Follmar, Keith E.
    Condron, Sara A.
    Turner, Immanuel I.
    Nathan, Jaimie D.
    Ludwig, Kirk A.
    SURGICAL INFECTIONS, 2008, 9 (02) : 195 - 200